1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Θετικών Επιστημών
  4. Τμήμα Χημείας
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/10486
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorKostoula, A.en
dc.contributor.authorKakafika, A.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M.en
dc.date.accessioned2015-11-24T16:56:46Z-
dc.date.available2015-11-24T16:56:46Z-
dc.identifier.issn1074-2484-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/10486-
dc.rightsDefault Licence-
dc.subjecthypertriglyceridemiaen
dc.subjectc-reactive proteinen
dc.subjectfibrinogenen
dc.subjectpaf-ahen
dc.subjectc-reactive proteinen
dc.subjectplatelet-activating-factoren
dc.subjectrandomized controlled trialen
dc.subjectcoronary-heart-diseaseen
dc.subjectapparently healthy-menen
dc.subjectmicronized fenofibrateen
dc.subjectcardiovascular-diseaseen
dc.subjectinsulin-resistanceen
dc.subjectgene-expressionen
dc.subjectreceptor-alphaen
dc.titleEffect of fenofibrate on serum inflammatory markers in patients with high triglyceride valuesen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondary<Go to ISI>://000226161600005-
heal.identifier.secondaryhttp://cpt.sagepub.com/content/9/1/27.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2004-
heal.abstractBackground: Atherosclerosis is the leading cause of death in developed countries. Although the mechanisms that underlie this process are not well defined, it has been proposed that atherosclerosis is mainly an inflammatory disease. In this context, a number of inflammatory markers have been studied for their ability to predict future cardiovascular events in asymptomatic individuals or patients with established atherosclerotic disease. Methods and Results: The aim of our study was to evaluate the effect of micronized fenofibrate on serum inflammatory markers, such as C-reactive protein, fibrinogen, and plasma platelet-activating factor acetylhydrolase (PAF-AH) in patients with high triglyceride values. An analysis of baseline values revealed that hypertriglyceridemic patients (n = 58) exhibit an atherogenic phenotype, characterized not only by elevated lipid values but also by high concentrations of serum inflammatory markers. Along with the improvement in serum lipid profile (reduction in triglycerides and total cholesterol, low-density lipoprotein, and non-high-density lipoprotein-cholesterol, with a concomitant increase in high-density lipoprotein-cholesterol levels), fenofibrate administration significantly reduced the values of serum inflammatory markers by 34%, 9.5%, and 24.8% for C-reactive protein, fibrinogen, and plasma PAF-AH, respectively. However, with the exception of PAF-AH, these reductions in inflammatory markers were not correlated with the changes in lipid values. Conclusions: In addition to its well-known hypolipidemic effects, fenofibrate may also possess significant anti-inflammatory properties that can contribute its antiatherogenic effect.en
heal.publisherSageen
heal.journalNameJournal of Cardiovascular Pharmacology and Therapeuticsen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Show simple item record
Files in This Item:
File Description SizeFormat 
Tsimihodimos-2004-Effect of fenofibrat.pdf1.31 MBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons